STATEN ISLAND, N.Y., Sept. 12, 2023 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, today announced that a presentation was given by Acurx Executive Chairman, Robert J. DeLuccia, at the World Antimicrobial Resistance Scientific Congress on September 7, 2023. In his presentation at the Innovation Showcase session, he highlighted that the Company anticipates completing enrollment of the 36 patients required for an interim review of the Phase 2b data by the Independent Data Monitoring Committee (IDMC) in the coming months.
Read more at prnewswire.comAcurx Announces Presentation and Update of Its pol IIIC R&D Pipeline at the World Antimicrobial Resistance Scientific Congress
PR Newswire - Press Release
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
/Super%20Micro%20Computer%20Inc%20logo%20on%20building-by%20Poetra_RH%20via%20Shutterstock.jpg)
